Real-World Evidence and Life-Cycle Health Technology AssessmentDeirdre Weymann from Simon Fraser University (Cananda) presents a case study of entrectinib in NTRK fusion positive solid tumours

16 June 2025, 4:30 pm

Precision health technologies frequently lack comparative evidence of safety, effectiveness, and value, challenging conventional regulatory and reimbursement processes and delaying patient access. Canadian researcher Deirdre Weymann presents a life-cycle health technology assessment framework for addressing this evidentiary uncertainty grounded in real-world evidence generated within healthcare systems. The presentation centres on a case study application to entrectinib, a TRK-inhibitor with conditional authorization for tumour-agnostic use in NTRK fusion positive solid tumours.

Deirdre Weymann presents her findings on Mon, 16 June 2025 at 16.30 hrs at the Hamburg Center for Health Economics.